Cargando…

Tumour necrosis factor-α levels are elevated in adolescent patients with juvenile idiopathic arthritis on etanercept therapy

Detalles Bibliográficos
Autores principales:	Radziszewska, Anna, Fisher, Corinne, Suffield, Linda, Kumaran, Geevithan, Sen, Debajit, Ioannou, Yiannis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190932/ http://dx.doi.org/10.1186/1546-0096-12-S1-P128

Ejemplares similares

Association of Anxiety With Pain and Disability but Not With Increased Measures of Inflammation in Adolescent Patients With Juvenile Idiopathic Arthritis
por: Hanns, Laura, et al.
Publicado: (2020)

Juvenile arthritis disease activity score is a better reflector of active disease than the disease activity score 28 in adults with polyarticular juvenile idiopathic arthritis
por: Wu, Qiong, et al.
Publicado: (2016)

Circulating complexes between tumour necrosis factor‐alpha and etanercept predict long‐term efficacy of etanercept in juvenile idiopathic arthritis
por: Kahn, Robin, et al.
Publicado: (2016)

Challenges in the management of juvenile idiopathic arthritis with etanercept
por: Pain, Clare E, et al.
Publicado: (2009)

Etanercept in juvenile idiopathic arthritis: Who will benefit?
por: Otten, MH, et al.
Publicado: (2011)

Developing and Evaluating JIApp: Acceptability and Usability of a Smartphone App System to Improve Self-Management in Young People With Juvenile Idiopathic Arthritis
por: Cai, Ran A, et al.
Publicado: (2017)

Efficacy and safety of Etanercept therapy in juvenile idiopathic arthritis
por: Lazareva, Arina, et al.
Publicado: (2011)

Etanercept treatment in juvenile idiopathic arthritis: The Polish registry
por: Żuber, Zbigniew, et al.
Publicado: (2011)

Clinical remission in juvenile idiopathic arthritis after termination of etanercept
por: Postępski, Jacek, et al.
Publicado: (2012)

Inflammatory Changes of the Lumbar Spine in Children and Adolescents With Enthesitis-Related Arthritis: Magnetic Resonance Imaging Findings
por: Vendhan, Kanimozhi, et al.
Publicado: (2014)

The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
por: Alfantaki, SA, et al.
Publicado: (2011)

Discontinuation of etanercept after clinical remission in patients with juvenile idiopathic arthritis
por: Cohen, Jean-David, et al.
Publicado: (2012)

The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
por: Livermore, P, et al.
Publicado: (2016)

Influence of etanercept on leptin and ghrelin secretion in children with juvenile idiopathic arthritis
por: Maciejewska-Paszek, Izabela, et al.
Publicado: (2017)

Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
por: Öman, Anders, et al.
Publicado: (2021)

Enthesitis related arthritis- 2 distinct clinical phenotypes?
por: Fisher, Corinne, et al.
Publicado: (2011)

PReS-FINAL-1009: Antioxidant superoxide dismutase activity is paradoxically normal in juvenile systemic lupus erythematosus
por: Radziszewska, A, et al.
Publicado: (2013)

Etanercept discontinuation in a cohort of juvenile idiopathic arthritis patients: etanercept inefficacy but not intolerance is associated with oral corticosteroid use
por: Southwood, TR, et al.
Publicado: (2008)

Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
por: Beukelman, Timothy, et al.
Publicado: (2021)

Depressive symptoms, pain and disability for adolescent patients with juvenile idiopathic arthritis: results from the Childhood Arthritis Prospective Study
por: Hanns, Laura, et al.
Publicado: (2018)

When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis
por: Prince, FHM, et al.
Publicado: (2008)

The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
por: Trachana, M, et al.
Publicado: (2011)

In vitro effects of etanercept on the development of different T cell subsets in patients with juvenile idiopathic arthritis
por: Cimaz, Rolando, et al.
Publicado: (2011)

Indirect comparison of etanercept and abatacept efficacy and safety in patients with polyarticular juvenile idiopathic arthritis
por: Loskutova (Konopelko), OU, et al.
Publicado: (2014)

Distinct Effects of Methotrexate and Etanercept on the B Cell Compartment in Patients With Juvenile Idiopathic Arthritis
por: Glaesener, Stephanie, et al.
Publicado: (2014)

Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
por: Klotsche, Jens, et al.
Publicado: (2021)

No benefit of the combination therapy etanercept and methotrexate compared to etanercept mono therapy in juvenile idiopathic arthritis – a matched pair analysis
por: Schmeling, Heinrike, et al.
Publicado: (2012)

PReS-FINAL-1017: Antioxidant superoxide dismutase activity is elevated in jia but not associated with disease activity
por: Radziszewska, A, et al.
Publicado: (2013)

The pain trajectory of juvenile idiopathic arthritis (JIA): translating from adolescent patient report to behavioural sensitivity in a juvenile animal model
por: Learoyd, Annastazia E., et al.
Publicado: (2019)

Intra-articular corticosteroid injections in juvenile idiopathic arthritis
por: Carrasco, Roberto, et al.
Publicado: (2014)

An in-depth analysis of young people's experience of their juvenile idiopathic arthritis (JIA) once receiving Etanercept
por: Livermore, P, et al.
Publicado: (2008)

Early Prediction of Clinical Response to Etanercept Treatment in Juvenile Idiopathic Arthritis Using Machine Learning
por: Mo, Xiaolan, et al.
Publicado: (2020)

Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
por: Levälampi, Tiina, et al.
Publicado: (2023)

Anti-tumour necrosis factor (anti-TNF) in the treatment of juvenile idiopathic arthritis-associated uveitis
por: Rivarola, C, et al.
Publicado: (2008)

Bone mineral density improvement after one year of treatment with etanercept in patients with juvenile idiopathic arthritis
por: Susic, G, et al.
Publicado: (2008)

Multicentric Castleman's Disease (CD) in juvenile idiopathic arthritis (JIA) treated with etanercept: coincidence or causal relationship?
por: Rossi, L, et al.
Publicado: (2008)

PReS-FINAL-2096: Herpes virus infections in patients with juvenile idiopathic arthritis (JIA) treated with etanercept
por: Nicolai, R, et al.
Publicado: (2013)

Correlation of ultrasonography synovitis with disease activity and clinical response to etanercept treatment in juvenile idiopathic arthritis patients
por: Zhou, Li, et al.
Publicado: (2019)

Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use
por: van Straalen, Joeri W, et al.
Publicado: (2021)

Plasma Glycosaminoglycans in Children with Juvenile Idiopathic Arthritis Being Treated with Etanercept as Potential Biomarkers of Joint Dysfunction
por: Wojdas, Magdalena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sveq64h5358gscfvgcivsjr1pf